Group 1 - The core event revolves around a dramatic power struggle at Sinovac Biotech, highlighted by a special shareholders' meeting where the current chairman, Li Jiaqiang, called for a recess, but the meeting continued under director Lu Yulin's leadership, resulting in a vote [2][9]. - Sinovac announced a staggering special dividend plan totaling up to approximately $7.5 billion, which includes a $55 special cash dividend per share, a $19 second special cash dividend, and a third special cash dividend ranging from $20 to $50 per share, potentially leading to a total dividend of $124 per share [3][11]. - The company’s financial performance has been volatile, with revenues peaking at $19.375 billion in 2021 but plummeting to $1.493 billion in 2022 and $448 million in 2023, alongside a net profit drop from $14.46 billion in 2021 to a loss of $258 million in 2023 [5][11]. Group 2 - The power struggle dates back to 2016 when co-founders Yinxing Dong and Pan Aihua had a falling out over the company's privatization plans, leading to a prolonged conflict involving various capital factions [6][7]. - The conflict escalated in 2018, resulting in a series of aggressive tactics, including stock dilution and boardroom battles, which ultimately led to a six-year trading suspension on NASDAQ due to governance issues [8][9]. - As of July 9, 2023, a new round of control disputes has emerged, with shareholders voting to remove the current board and elect new members backed by Sequoia Capital, although the existing board claims the vote lacks legal validity [9][10].
75亿美元分红难平资本角力:科兴生物董事会现“双版本”结果,十年内斗僵局难破